TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTAGENE MARALEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA. (12th June 2019) - Siddiqi, T.; Dorritie, K.A.; Soumerai, J.D.; Stephens, D.M.; Dubovsky, J.A.; Gillenwater, H.H.; Gong, L.; Thorpe, J.; Yang, L.; Wierda, W.G.